Quantification of regurgitation in mitral valve prolapse with four-dimensional flow cardiovascular magnetic resonance

Ricardo A. Spampinato1†, Cosima Jahnke2†, Gerard Crelier3, Frank Lindemann2, Florian Fahr1, Monika Czaja-Ziołkowska2, Franz Sieg1, Elfriede Strodtrees1, Gerhard Hindricks2, Michael A. Borger1 and Ingo Paetsch2

Abstract

Background: Four-dimensional cardiovascular magnetic resonance (CMR) flow assessment (4D flow) allows to derive volumetric quantitative parameters in mitral regurgitation (MR) using retrospective valve tracking. However, prior studies have been conducted in functional MR or in patients with congenital heart disease, thus, data regarding the usefulness of 4D flow CMR in case of a valve pathology like mitral valve prolapse (MVP) are scarce. This study aimed to evaluate the clinical utility of cine-guided valve segmentation of 4D flow CMR in assessment of MR in MVP when compared to standardized routine CMR and transthoracic echocardiography (TTE).

Methods: Six healthy subjects and 54 patients (55 ± 16 years; 47 men) with MVP were studied. TTE severity grading used a multiparametric approach resulting in mild/mild-moderate (n = 12), moderate-severe (n = 12), and severe MR (n = 30). Regurgitant volume (RVol) and regurgitant fraction (RF) were also derived using standard volumetric CMR and 4D flow CMR datasets with direct measurement of regurgitant flow (4DFdirect) and indirect calculation using the formula: mitral valve forward flow - left ventricular outflow tract stroke volume (4DFindirect).

Results: There was moderate to strong correlation between methods (r = 0.59–0.84, p < 0.001), but TTE proximal isovelocity surface area (PISA) method showed higher RVol as compared with CMR techniques (PISA vs. CMR, mean difference of 15.8 ml [95% CI 9.9–21.6]; PISA vs. 4DFindirect, 17.2 ml [8.4–25.9]; PISA vs. 4DFdirect, 27.9 ml [19.1–36.8]; p < 0.001). Only indirect CMR methods (CMR vs. 4DFindirect) showed moderate to substantial agreement (Lin's coefficient 0.92–0.97) without significant bias (mean bias 1.05 ± 26 ml [− 50 to 52], p = 0.757). Intra- and inter-observer reliability were good to excellent for all methods (ICC 0.87–0.99), but with numerically lower coefficient of variation for indirect CMR methods (2.5 to 12%).

Conclusions: In the assessment of patients with MR and MVP, cine-guided valve segmentation 4D flow CMR is feasible and comparable to standard CMR, but with lower RVol when TTE is used as reference. 4DFindirect quantification has higher intra- and inter-technique agreement than 4DFdirect quantification and might be used as an adjunctive technique for cross-checking MR quantification in MVP.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
**Introduction**

In past years, considerable advances in surgical treatment options of mitral regurgitation (MR) resulted in improved life expectancy, but prognosis and clinical decision making with regard to timing of surgery strongly depend on the accurate quantification of MR using cardiac imaging techniques [1].

Trans-thoracic multiparametric echocardiography (TTE) is at the forefront and widely recognized as the non-invasive standard of reference for assessment of MR [2] including proximal isovelocity surface area (PISA) determination with its typical methodological limitations (i.e. the reliance on geometric assumptions of a hemispheric flow convergence region (FCR), and Doppler measurement angle dependency). Hence, and particularly in borderline cases [3], a multimodality approach employing standard volumetric cardiovascular magnetic resonance (CMR) has been incorporated [4, 5].

In addition, time-resolved, three-dimensional (3D) full anatomic coverage with three-directional velocity-encoded phase contrast CMR, referred to as four-dimensional (4D) flow CMR has further broadened the diagnostic armamentarium [6] and has been proposed for quantification of blood flow volumes across the mitral valve. The potential benefit of 4D flow CMR in relation to the 2D CMR phase contrast (PC) technique, is the acquisition in one single examination of a “three-directional” velocity-encoding data-set. Permitting to place in a retrospective manner an analysis plane in any location perpendicular to blood flow, which may be critically important for quantify peak velocity and visualization of blood flow in cases of complex valve flow jets.

Previous 4D flow CMR studies using retrospective valve tracking or direct jet analysis, have been carried out in functional MR [7, 8], congenital heart disease [9], small patient groups [10], or in mixed patient populations [11, 12]. However, it can be speculated that these data cannot be generalized to patients with mitral valve prolapse (MVP) because concomitant MR may be challenging to assess due to geometrical asymmetry of the orifice area (“slit-like”) and highly dynamic and eccentric MR jets. Thus, data on the clinical utility of 4D flow CMR in patients with MVP are still scarce. Therefore, we aimed to evaluate the value of cine-guided valve segmentation of 4D flow CMR in assessment of regurgitation in MVP when compared to standardized routine CMR and TTE.

**Material and methods**

**Study population**

Between June 2018 and December 2019, six healthy subjects and 58 patients with known MVP and sinus rhythm, who were referred to our outpatient clinic for follow up and gave written informed consent, were prospectively enrolled in an institutional review board–approved study. Exclusion criteria were previous valve surgery, concomitant aortic valve disease > grade I, intra-cardiac shunts, other known causes of cardiomyopathy, or typical contraindications for CMR imaging. The final study cohort consisted of 60 subjects (55 ± 16 years, 47 male); reasons for withdrawal from study were incapability to tolerate the supine position during the CMR examination (n = 1), incomplete 4D flow CMR dataset due to logistic reasons (n = 1) and low 4D flow CMR image quality due to multiple premature ventricular contractions during image data acquisition (n = 2).

Patient demographics and clinical data were recorded during initial presentation with TTE and CMR measurements carried out within a mean time frame of 6.5 h (mean 391 min, 95% CI: 125–658; range, 30–7320 min). Based on a TTE multiparametric approach [2] grading of MR severity resulted in three study groups: mild/mild-moderate (MR grade 1 + /2 +, n = 12), moderate-severe (MR grade 3 +, n = 12), and severe (MR grade 4+, n = 30). In order to evaluate agreement with CMR quantification methods, regurgitant volume (RVol) and regurgitant fraction (RF) were also derived from standard volumetric CMR and 4D flow CMR.

**Standard echocardiography**

TTE was performed using standard commercially available ultrasound machines (Vivid E95, General Electric Healthcare, Chicago, Illinois, USA; or Acuson SC2000 Prime, Siemens Healthcare, Erlangen, Germany) equipped with 2.25–4.25 MHz transducers. Evaluation of MVP was carried out by one cardiologist (RAS), expert in TTE and valvular heart diseases, blinded to the results of CMR exams. TTE were acquired using standard views and Doppler measurements were evaluated as the average of three cycles. Color flow Doppler interrogation of the MR jet was performed in multiple views. Vena contracta (VC) was measured in the modified parasternal long-axis view as the narrowest portion of the jet. PISA method, effective regurgitant orifice area (EROA), RVol, and RF were calculated as recommended [2]. Efforts were made to obtain a well-defined hemispheric FCR avoiding...
constraint. When necessary angle correction was advised to improve the accuracy. PISA radius was measured at the time of peak regurgitant velocity.

Following graduation scheme was used: mild (VC < 3 mm, EROA < 20 mm², RVol < 30 ml, RF < 30%), mild-moderate (VC 3–6 mm, EROA 20–29 mm², RVol 30–44 ml, RF 30–39%), moderate-severe (VC 3–6 mm, EROA 30–39 mm², RVol 45–59 ml, RF 40–49%), and severe (VC ≥ 7 mm, EROA ≥ 40 mm², RVol ≥ 60 ml, RF ≥ 50%). In case of discrepancies (in 13 of 54 MR cases) quantitative methods were conclusive.

**Standard volumetric CMR data acquisition and analysis**

All CMR examinations were performed on dedicated 1.5 T CMR system (Ingenia, Philips Healthcare) equipped with Omega HP gradients (45 mT/m, 200 T/m/s) using a 28-element array coil with full in-coil signal digitalization. Image data acquisition adhered to current recommendations and image data analysis was carried out off-line [5] using IntellispacePortal analysis software (release 9.0.1, Philips Healthcare). All readers were fully blinded to clinical and TTE data. For cine CMR, balanced steady-state free precession (bSSFP) sequences with retrospective electrocardiographic (ECG) gating were used during repetitive breath-holding. All standard cardiac geometries were acquired (multiple, gapless short-axis slices covering the entire left ventricle (LV) and 2-, 3- and 4-chamber views). Reconstructed in-plane spatial resolution was 1.3 ± 1.3 mm² with a slice thickness of 8.0 mm; temporal resolution of cine bSSFP sequences was < 30 ms depending on heart rate. In addition, two-dimensional PC flow measurements were performed in the ascending aorta with the imaging plane 10 mm above the aortic valve and perpendicular to the flow direction; velocity encoding 200 cm/s was individually adapted if needed. Image data acquisition was ECG gated, with in-plane spatial resolution of 1.4 ± 1.4 mm², temporal resolution 35 phases per cardiac cycle, slice thickness 8 mm, and during a 12–15 s breath-hold. Through-plane phase-contrast derived measurements were: aortic stroke volume (AoSV), aortic systolic forward flow volume (AoFF), and aortic diastolic backward flow volume (AoBF). Cine short axis images were used to measure LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), and stroke volume (SV). With standard volumetric CMR quantification of MR was performed indirectly. RVol was calculated by subtracting aortic systolic flow from LV SV. The RF was then calculated by dividing the RVol by the LV SV and expressed in percent: RVol(ml) = LVSV – AoFF and RF(%) = (RVol/ LVSV) × 100 with severity graded as [13] mild (RF < 20%), mild-moderate (RF 20–29%), moderate-severe (RF 30–39%), and severe (RVol ≥ 55 ml, RF ≥ 40%).

**4D flow CMR data acquisition and analysis**

4D flow CMR acquisitions were obtained as the last sequence of each CMR study. Data were acquired by two cardiologists (CJ and IP) with over 20 years of experience in CMR imaging. The 4D flow CMR approach consisted in a LV long-axis alienated volume acquisition, planned in a four-chamber geometry. The number of slices has been adapted individually in order to ensure, from the two- and three-chamber views, a full coverage of left atrial, LV outflow tract (LVOT) and LV, encompassing the mitral valve during the whole cardiac cycle. Two different 4D flow CMR sequences were acquired with adapted velocity encoding to ensure no aliasing for the anterograde (stroke volume) and retrograde (RVol) mitral blood flow quantification. Reported acquisition nominal times for each 4D flow protocol were typically 5–10 min. The protocol used a field-of-view of 310 ± 15 mm with 70 ± 9 mm stack thickness reconstructed in 28 ± 3 slices of 2.5 mm thickness resulting in an acquired spatial resolution of 0.8–1.47 × 0.8–1.47 × 2.5 mm³. Flip angle was 10°, echo time/repetition time was 3.3/14 to 4.3/7.5 resulting in 22–56 ms (mean 38 ± 6 ms) temporal resolution.

4D flow CMR was supplemented with 2D cine acquisitions of LV two-, three-, and four-chamber views plus LVOT and mitral valve in-plane multi-slice 2D-cine geometries for high-resolution anatomical guidance, which were interpolated with the 4D flow datasets. In such a way that in-plane cine views as anatomical orientations, were available for mitral valve and LVOT segmentation ("cine-guided valve segmentation").

**Flow quantification**

Acquisition details are presented in Additional file 1 and depicted in Fig. 1. Post-acquisition, offline analysis was performed using commercially available custom software (GTFlow, GyroTools, Zurich, Switzerland). Subjects were analyzed in a blinded fashion (2 weeks apart from first TTE study) by a cardiologist (RAS) with 5 years clinical and research experience in CMR. Two readers for indirect (MCZ) and direct (FF) quantification obtained training and feedback in a series of 10 subjects. These feedback sessions were not included. Measurements were then repeated with 3 weeks between analyses to obtain intra- and inter-observer variability.

For indirect 4D flow CMR quantification (4DFindirect), the diastolic blood forward flow or stroke volume through the mitral valve (MV-SV4DFlow) and the systolic net blood flow or stroke volume through the LVOT (LVOT-SV4DFlow) were analyzed. Mitral valve regurgitant volume (RVolindirect) was calculated as the subtraction between MV-SV4DFlow and LVOT-SV4DFlow, and the RF as follow: RFindirect = (RVolindirect/MV-SV4DFlow) × 100.
Additionally, the 4D flow CMR dataset with the higher venc was used to delineate the regurgitant jet for direct quantification (4DF\textsubscript{direct}) as previously described [14, 15]. A ROI was located using the PC image and the direct mitral valve regurgitant volume (RVol\textsubscript{direct}) derived. 

\[
\text{RF}_{\text{direct}} = \left( \frac{\text{RVol}_{\text{direct}}}{\text{MV-SV}_{4D\text{-flow}}} \right) \times 100.
\]

**Statistical analysis**

Data are presented as mean (SD), median (25th–75th percentile), or frequency (percent) as appropriate. Statistical differences between groups were assessed using Student's t-test for continuous variables or Fisher's exact test for categorical variables. Multigroup comparisons of continuous variables were performed using an analysis of variance (ANOVA). Pearson correlation coefficient, Bland–Altman plots, and intraclass correlation coefficient (ICC) were used to assess correlations and agreements between methods. Then, Lin's concordance correlation coefficient was calculated, to assess the concordance of continuous data with the following scale to describe the strength of agreement: > 0.99 indicates almost perfect agreement; 0.95–0.99, substantial agreement; 0.90–0.95, moderate agreement; and < 0.90, poor agreement. Additionally, rate of agreement for MR grading was evaluated by calculating k-statistics. Inter- and intra-observer coefficient of variation were determined as the deviation between (re)-measurements divided by the mean of both measurements. The mean absolute difference and the ICC were also determined. Finally, for internal validation, net forward flow through the mitral valve
was considered the reference SV in the control group and through the pulmonary vale in 8 randomly selected cases of the MR group (validation subgroup, n=14). Two-tailed p-values<0.05 were considered statistically significant. Analyses were performed using SPSS (version 20, Statistical Package for the Social Sciences, International Business Machines, Inc., Armonk, New York, USA).

Results

4D flow CMR analysis was successfully performed in 97% of subjects. 4DF\textsubscript{indirect} quantification could be performed in all patients and controls (n=60), while a 4DF\textsubscript{direct} assessment in only 46 patients of the MR group (n=54). A 2D-TTE derived PISA method could be obtained in all patients with MVP. There were no differences in blood pressure or heart rate values between CMR and TTE studies (132 ± 18 / 73 ± 11 vs. 133 ± 17 / 75 ± 11 mmHg, and 67 ± 11 vs. 68 ± 11 beats per minutes, p>0.164). Post-processing times were shorter with 4DF\textsubscript{indirect} method (indirect: 4.2 ± 0.7 min vs. direct: 6.4 ± 1.4 min; mean difference: 2.2 ± 1.3 min, p<0.001).

Demographic and baseline patient characteristics are presented in Table 1. MR patients were older and more prone to have comorbidities than the control group. CMR and TTE characteristics are shown in Table 2. Patients with severe MR had higher TTE and CMR derived LVEDV and LV SV compared with MR grade 1+/2+ and 3+\textsubscript{a}, but similar LVOT SV or forward SV values reflecting progressively higher RVol and RF values through the groups.

Table 1 Patient characteristics

|                     | Controls (n=6) | MR group (n=54) |
|---------------------|---------------|-----------------|
| Age, years          | 31 ± 5        | 58 ± 14         |
| Male, n (%)         | 5 (83)        | 42 (78)         |
| BSA, m\textsuperscript{2} | 1.9 ± 0.2    | 1.9 ± 0.2       |
| Coronary artery disease, n (%) | 0 | 6 (11) |
| Hypertension, n (%) | 0             | 39 (72)         |
| Diabetes, n (%)     | 0             | 6 (11)          |
| Dyslipidemia, n (%) | 0             | 22 (41)         |
| NYHA II/III/IV, n   | 6/0/0         | 22/19/13        |
| Mitral valve prolapse | –             | –                |
| Posterior leaflet, n | –             | 37               |
| Anterior leaflet, n | –             | 3                |
| Bileaflet (Barlow’s disease), n | – | 14 (3) |

\textsuperscript{a}MR mitral regurgitation, BSA body surface area, NYHA New York Heart Association Functional Classification. Unless otherwise specified, values are expressed as mean±SD.

Agreement between methods

Overall the RVol and RF measurements assessed by PISA, CMR, and 4D flow methods showed moderate to strong correlation (Fig. 2). Nevertheless, PISA derived values were significantly different from standard and 4D flow CMR methods, with higher RVol and RF (Table 3 and Fig. 3).

Bland–Altman plots demonstrated narrower limits of agreements for both indirect CMR methods. The small mean differences between 4DF\textsubscript{indirect} and CMR derived RVol and RF were not significant (1.1 ml and 1.2%, respectively). In addition, calculation of Lin’s concordance correlation coefficients confirmed moderate to substantial agreement between standard CMR and 4DF\textsubscript{indirect} for the assessment of RVol and RF, respectively. All other comparisons showed only poor agreement (Table 4). Moreover, agreement in grading MR severity was higher between standard CMR and 4DF\textsubscript{indirect} than 4DF\textsubscript{direct} (moderate, kappa=0.542 vs. fair, kappa=0.383; p<0.001); with 39 of 54 patients (72%) having the same MR grade with the 4DF\textsubscript{indirect} method. All controls were classified as none/trace MR in both indirect CMR methods. Finally, compared with an integrative TTE multiparametric approach, MR severity was reclassified more than one grade scale in 5 patients with the 4DF\textsubscript{direct} method, in only 1 patient with the 4DF\textsubscript{indirect} method, and in no patient with the standard CMR method, with consequently better kappa-statistics (Table 3).

When comparing the two 4D flow methods, there was a strong correlation assessing RVol (r=0.764, p<0.001), but only a weak to moderate correlation (r=0.472, p<0.001) for the RF values. 4DF\textsubscript{indirect} method derived RVol values were statistically higher than those derived from 4DF\textsubscript{direct} method, with a mean difference of 9.2 ml (95% CI 2.4 to 16.0, p=0.009), but there were no statistical differences in RF values (4.4% [95% CI -0.4 to 9.3, p=0.069]).

Consistency and reproducibility of 4D flow quantification

In the validation subgroup (n=14), the mean difference of 3.1 ml (95% CI, −8.8 to 2.6; p=0.259) between net forward flow volume through the LVOT (75.4 ±16.5 ml) and the reference valve (78.5 ±18.8 ml) was not significant (internal reference). Moreover, the lower values of the net forward flow volume through the LVOT by 4D flow compared to the 2D PC flow measurements (external reference) were also not significant (mean difference: −7 ml, 95% CI, −17 to 3.2; p=0.162).

Reproducibility was tested in all subjects. The intraobserver coefficients of variation (CV) for analysis of MV-SV\textsuperscript{4D_flow} and LVOT-SV\textsuperscript{4D_flow} by 4DF\textsubscript{indirect} method were 6.5 ±5% and 4.6 ±4.9%, with a mean difference of
Table 2  Multiparametric TTE classification of MR: TTE, standard, and 4D flow CMR values

| Parameter                                | Control (6) | MR group (54) | MR Grade 1 + /2 + (12) | MR Grade 3 + (12) | MR Grade 4 + (30) |
|------------------------------------------|-------------|---------------|------------------------|-------------------|-------------------|
| **Echocardiographic parameters**         |             |               |                        |                   |                   |
| LVEDV, ml                                | 133 ± 28    | 175 ± 67      | 133 ± 44*              | 140 ± 37*         | 206 ± 69          |
| LVESV, ml                                | 48 ± 9      | 58 ± 28       | 52 ± 21                | 44 ± 13           | 67 ± 33           |
| LVEF, %                                  | 64 ± 4      | 67 ± 7        | 61 ± 6*                | 68 ± 6            | 68 ± 6            |
| LVOT SV, ml                              | 80 ± 2      | 71 ± 16       | 73 ± 14                | 80 ± 13           | 67 ± 17           |
| EROA, cm²                                | n.a         | 0.49 ± 0.28   | 0.16 ± 0.13*           | 0.36 ± 0.09*      | 0.68 ± 0.22       |
| RVol, ml *                               | n.a         | 73 ± 39       | 22 ± 16*               | 54 ± 8*           | 101 ± 25          |
| RF, % *                                  | n.a         | 47 ± 18       | 21 ± 10*               | 40 ± 4*           | 60 ± 8            |
| Vena contracta, cm                       | n.a         | 0.62 ± 0.29   | 0.29 ± 0.15*           | 0.60 ± 0.09*      | 0.76 ± 0.09       |
| E wave, m/s                              | 0.77 ± 0.21 | 1.36 ± 0.38*  | 0.92 ± 0.19*           | 1.22 ± 0.16*      | 1.58 ± 0.31       |
| **PW Doppler parameters**                |             |               |                        |                   |                   |
| MV SV, ml                                | 84 ± 3      | 139 ± 42*     | 96 ± 27*               | 124 ± 16*         | 163 ± 38          |
| RVol, ml                                 | 3 ± 3       | 69 ± 42*      | 22 ± 17*               | 48 ± 13*          | 96 ± 36           |
| RF, % *                                  | 4 ± 3       | 45 ± 18*      | 21 ± 12*               | 38 ± 7*           | 58 ± 11           |
| **CMR parameters**                       |             |               |                        |                   |                   |
| LVEDV, ml                                | 169 ± 24    | 220 ± 71*     | 172 ± 50*              | 186 ± 45*         | 254 ± 70          |
| LVESV, ml                                | 66 ± 12     | 85 ± 38*      | 70 ± 36                | 68 ± 25           | 98 ± 39           |
| LV SV, ml                                | 103 ± 14    | 135 ± 38*     | 102 ± 24*              | 117 ± 23*         | 156 ± 35          |
| LVEF, %                                  | 63 ± 5      | 62 ± 7        | 61 ± 10                | 64 ± 7            | 62 ± 6            |
| Aorta forward flow, ml                   | 98 ± 12     | 78 ± 21*      | 82 ± 19                | 80 ± 16           | 76 ± 23           |
| Aorta net flow (SV), ml                  | 97 ± 11     | 74 ± 19*      | 77 ± 19                | 74 ± 12           | 72 ± 22           |
| RVol, ml                                 | 5 ± 4       | 57 ± 34*      | 21 ± 16*               | 37 ± 11*          | 80 ± 26           |
| RF, % *                                  | 4 ± 3       | 41 ± 17*      | 20 ± 13*               | 33 ± 7*           | 53 ± 11           |
| **4D flow CMR (indirect)**               |             |               |                        |                   |                   |
| MV SV, ml                                | 93 ± 16     | 124 ± 39      | 99 ± 25*               | 119 ± 23          | 135 ± 44          |
| LVOT net flow (SV), ml                   | 86 ± 15     | 68 ± 16*      | 73 ± 13                | 77 ± 9*           | 62 ± 17           |
| RVol, ml **                              | 7 ± 6       | 56 ± 35*      | 26 ± 16*               | 43 ± 16*          | 73 ± 36           |
| RF, % **                                 | 7 ± 6       | 42 ± 16*      | 24 ± 11*               | 35 ± 6*           | 52 ± 13           |
| **4D flow CMR (direct)**                 |             |               |                        |                   |                   |
| RVol, ml ***                             | n.a         | 51 ± 25       | 28 ± 12*               | 43 ± 15           | 59 ± 25           |
| RF, % ***                                | n.a         | 40 ± 16       | 25 ± 9*                | 35 ± 9            | 46 ± 16           |

**TTE** transthoracic echocardiography, **MR** mitral valve regurgitation, **CMR** cardiac magnetic resonance, **LVEDV** left ventricular end-diastolic volume, **LVESV** left ventricular end-systolic volume, **LVEF** left ventricular ejection fraction, **LVOT** left ventricular outflow tract, **SV** stroke volume, **EROA** effective regurgitant orifice area, **RVol regurgitant volume (MR)**, **RF** regurgitant fraction (MR), **PW** pulse-wave, **MV** mitral valve. Values are expressed as mean ± SD. **2D-PISA method (n = 54); **4D flow indirect (n = 60) and **direct (n = 46) method. Differences reached statistical significance with: $ ^{5} $ control, $ ^{6} $ group “MR grade 3 + “, and $ ^{7} $ group “MR grade 4 + “.

1 ml (95% CI, −3.8 to 1.9; p = 0.513) and 1.1 ml (−2.3 to 0.2; p = 0.099), an absolute mean difference of 8.2 ml (6.2 to 10.2) and 3.3 ml (2.3 to 4.3), and excellent ICC of 0.982 (0.970–0.989; p < 0.001) and 0.979 (0.964–0.987; p < 0.001), respectively. The inter-observer CV were 11.9 ± 8% and 10.4 ± 10%, with a mean difference of 0.8 ml (95% CI, −4 to 5.6; p = 0.735) and 1 ml (−1.3 to 3.3; p = 0.390), an absolute mean difference of 14.7 ml (11.8 to 17.6) and 6.7 ml (5.2 to 8.3), and excellent ICC of 0.938 (0.896–0.963; p < 0.001) and 0.919 (0.865–0.952; p < 0.001), respectively.

The intra-observer CV for RVol quantification by 4DF direct method was 16.6 ± 12%, with a mean difference of 2.7 ml (95% CI, −5.3 to −0.1; p = 0.041), an absolute mean difference of 7.5 ml (5.9 to 9.0), and an excellent ICC of 0.971 (0.948–0.984; p < 0.001). The inter-observer CV was 32 ± 21%, with a mean difference of 3.1 ml (95% CI, −8.6 to 2.3; p = 0.257), an absolute mean difference of 15.2 ml (12.1 to 18.3), and a good ICC of 0.868 (0.762–0.927; p < 0.001).

Finally, inter- and intra-observer variability by 2D-PISA and standard CMR methods are also summarized in Table 5.
Discussion

The present prospective study aimed to evaluate the clinical utility of cine-guided valve segmentation of 4D flow CMR for the assessment of MR in MVP in direct comparison to standard CMR and TTE. The main findings can be summarized as follows: (1) in patients with MVP, quantification of RVol and RF by 4D flow CMR was feasible and reproducible; (2) strong correlation was observed between standard CMR and 4DF_{indirect} methods, with no significant bias; conversely, 4DF_{direct} significantly underestimated RVol as compared with all other methods; (3) 4DF_{indirect} showed better intra- and inter-technique agreement and reliability than 4DF_{direct} method; and (4) despite moderate to strong correlation between methods, PISA method systematically showed higher RVol and RF as compared with CMR techniques.

Recently 4D flow CMR was introduced and validated in vitro with phantom models [11], and first clinical
experiences with healthy subjects and patients with MR demonstrated its feasibility. However, previous studies have been performed in functional MR [7,8], congenital heart disease [8,15], small study groups [10,16], or in rather mixed patient populations [9,11,12,16]. In the present study we investigated the clinical utility of 4D flow CMR in a homogeneous group of MVP patients.

Table 4 Lin's concordance correlation coefficients to assess agreement between methods

| Method          | Lin's concordance correlation coefficient | 95%CI       |
|-----------------|-----------------------------------------|-------------|
| 2D-PISA vs. CMR | RVol                                    | 0.851       |
|                 | RF                                      | 0.852       |
| 2D-PISA vs. 4DFind | RVol                              | 0.841       |
|                 | RF                                      | 0.865       |
| 2D-PISA vs. 4DFdir | RVol                              | 0.538       |
|                 | RF                                      | 0.331       |
| CMR vs. 4DFind  | RVol                                    | 0.971       |
|                 | RF                                      | 0.922       |
| CMR vs. 4DFdir  | RVol                                    | 0.862       |
|                 | RF                                      | 0.596       |
| 4DFind vs. 4DFdir | RVol                               | 0.670       |
|                 | RF                                      | 0.448       |

Table 5 Intra- and inter-observer measurement variability

| Method                       | Bland–Altman* | ICC† | CV, % |
|------------------------------|---------------|------|-------|
| 4D flow CMR indirect method  |               |      |       |
| Intra-observer MV SV         | −1.0 (21 to −23) | 0.982 | 7     |
| Inter-observer MV SV         | 0.8 (37 to −36) | 0.938 | 12    |
| 4D flow CMR direct method    |               |      |       |
| Intra-observer MV RVol       | 2.7 (14 to −20) | 0.971 | 17    |
| Inter-observer MV RVol       | 3.1 (33 to −39) | 0.868 | 32    |
| Standard CMR method          |               |      |       |
| Intra-observer LV SV         | 1.5 (8 to −5)  | 0.998 | 2.5   |
| Inter-observer LV SV         | 2.7 (19 to −13) | 0.989 | 6     |
| 2D-PISA method               |               |      |       |
| Intra-observer MV RVol       | 2.1 (20 to −16) | 0.986 | 12    |
| Inter-observer MV RVol       | 3.2 (34 to −28) | 0.959 | 15    |

Fig. 3 Bland–Altman plots. Agreement of measurements of regurgitant volume (blue dots) and fraction (red dots) by 2D-echocardiographic flow convergence method (2D-PISA), standard cardiac magnetic resonance (CMR), and 4D flow CMR indirect and direct methods, in patients with mitral valve prolapse.

Quantification of regurgitation in MVP is particularly challenging since extensive changes in valve geometry often lead to adherent or eccentric jets. Thus, volumetric

2D-PISA 2-dimensional transthoracic echocardiography derived proximal isovelocity surface area, CMR standard cardiac magnetic resonance, 4D flow CMR indirect method, 4D flow CMR direct method, 95%CI 95% confidence interval

4D Flow CMR time-resolved, three-dimensional anatomic coverage, three-directional velocity-encoded phase contrast CMR, MV mitral valve, LVOT left ventricle outflow tract, SV stroke volume, RVol regurgitant volume, LV left ventricle, Ao FF aortic forward flow, 2D-PISA proximal isovelocity surface area, ICC intraclass correlation coefficient, CV coefficient of variation. *Mean difference (2-sided 95% confidence limits of agreement). † All P < 0.001
measurement techniques may be preferable in MVP since regurgitant volume and fraction can be derived without any assumptions about hemodynamic or shape and are generally not or only minimally affected by the direction of the MR jet or geometry of the mitral orifice. First clinical studies using 4D flow CMR for direct assessment of both atrioventricular valves demonstrated excellent agreement between SV through the valve of interest and ascending aorta [11], or between all four valves [12]. The present study data demonstrated that 4DF indirect is highly reproducible with higher concordance to standard CMR than 4DF direct. Recently, Fidock and colleagues [16] reported similar findings for primary MR. Nevertheless, they analyzed a small subgroup (n = 12), provided no direct comparison with TTE, and reported a rather low RVol (mean 28.6±2.5 ml). In the present study the higher mean RVol of 57±34 ml indicates that a substantial number of patients with high grade MR were included which will facilitate generalizability and applicability of our results in a clinical routine setting.

In the present study, 4DF direct quantification could not be performed in 8 patients of the MVP group (n = 54) due to difficulties to delineate the cross-sectional area of the MR jet due to poor visualization (n = 4), excessive aliasing (n = 1), or poor contrast between blood pool and the regurgitant jet (n = 3). Similarly, in a cohort of 44 children with congenital heart disease and atrioventricular valve regurgitation, Jacobs and colleagues reported that six patients (9%) were excluded due to concerns related to image quality including excessive aliasing on 4D flow (n = 1), movement during 4D flow acquisitions (n = 2), and poor visualization of the regurgitant jets (n = 3). Nevertheless, they reported a better concordance between standard CMR and 4D flow direct measurement of the regurgitant jet, as compared with an annular inflow indirect method, but with slightly superior performance in subjects with tricuspid regurgitation compared to those with MR [15]. Moreover and in accordance with our results, Feneis et al., in a cohort of 21 adults with tricuspid regurgitation (TR) and MR, showed that direct method was better for the assessment of TR, and the indirect method had a better diagnostic performance for the MR [10]. As mentioned by the authors, this could be explained because TR jets tend to be more central and laminar as compared to MR jets, which are more prone to be multiple, eccentric, and dynamic with systolic angulation change [14]. Which makes it challenging even with the use of retrospective valve tracking. This might explain the systematically lower values of RVol by 4DF direct method observed in our study. Moreover, as previously showed [17], in patients with prominent bileaflet MVP, the volumetric CMR method may underestimate the LVESV as it only considers the volume located between the apex and the mitral annulus, and neglects the volume that is contained within the prolapsed mitral leaflets at end systole (prolapsed volume). Which may lead to an overestimation of the RVol. In our cohort we identified 14 patients with bileaflet MVP. In this subgroup, the mean prolapsed volume was 8.7±4.8 ml. The corrected RVol tacking into account this prolapsed volume, as proposed from Vincenti et al., was accordingly significantly lower than the uncorrected RVol (30.4±20.4 ml vs 39±21.2 ml, p < 0.001). Notwithstanding, in this subgroup of patients, we observed no significant differences between uncorrected RVol by CMR and RVol by 4D flow (CMR: 39±21 ml, 4DF indirect: 42±32 ml, and 4DF direct: 37±17 ml, p > 0.68). It might be speculated that measuring the anterograde mitral blood flow (MV-SV 4D-flow) slightly above (ventricular side) or at the level of the mitral valve annulus may not discriminate between prolapsed volume and RVol. Nevertheless, retrograde mitral blood flow (RVol direct) was measured positioning the plane on the atrial side of the MV, and still the RVol by 4DF direct was significantly higher than the corrected RVol (n = 12; 37±17 ml vs 28±18 ml, p = 0.008). Difficulties in identifying the contour of the cross-sectional regurgitant jet area using the 4D flow PC images may have contributed to overestimation of the RVol by 4DF direct compared to corrected RVol, possibly due to applying slightly bigger ROI’s areas. However, the lack of a subgroup of patients with no MR and bileaflet MVP made the evaluation of this hypothesis not possible. Therefore, future studies will have to appraise this issue.

In addition, cine-guided valve segmentation provided better contrast of the borders of the mitral valve as compared with the contouring of the regurgitant jet in the 4D flow PC images. Aforementioned technical difficulties may also explain the observed longer post-processing time and higher inter-observer variability of the 4DF direct method (CV: 32% vs. 12%). Kamphuis et al. [9] demonstrated a shorter analysis time to quantify the flow over all 4 valves for automated versus manual tracking (14 min vs. 25 min) and reported an excellent reproducibility for the measurement of mitral valve flow (intra-observer, CV 5.2%; inter-observer, 5.6%). Additionally, Jacobs et al. [15], reported excellent post-processing times for assessment of atrioventricular valve regurgitation, using a semi-automated 4D flow CMR algorithm (indirect method 3.7 ± 1.9 min vs. direct method 3.1 ± 2.1 min, p = 0.114).

Even though, we still observed broad limits of agreement between standard CMR and 4DF indirect methods, the Lin’s coefficient showed moderate to substantial agreement and there were no systematic bias. These widespread limits of agreement may be expected to be more pronounced in the groups with MR 3+/4+, where the impact in grading of regurgitation should be
less decisive. Indeed, consistency in grading MR severity between standard CMR and 4DFindirect was clinically acceptable (kappa = 0.542; p < 0.001); with 75% of subjects having the same MR grade and 22% with only one scale misclassification. Only 2 of 60 subjects with MR 4+ by standard CMR were reclassified as MR 2+ by 4DFindirect. Importantly, all controls were classified as none/trace MR with both methods and no MR 1+ was reclassified as severe. Which, is a real scenario in the daily clinical practice. Other studies have showed similar limits of agreement when comparing two different methods of MR quantification [15, 18]. Calkoen et al. [14] found narrower limits of agreement between standard CMR and 4D flow (~12 to 20 ml), but they included a cohort with a mean RVol of 11 ± 6 ml (vs. 57 ± 34 ml in our study).

Finally, we observed higher values of RVol and RF by TTE PISA method as compared with CMR techniques. There is some data suggesting that PISA method might overestimate the RVol in organic MR when compared with CMR [18, 19]. In accordance with our study, Uretsky et al. [18] observed similar bias between TTE and CMR (mean difference of 16 ml with wide limits of agreement: -38 to 70 ml). This might be in part secondary to difficulties in contouring the dynamic FCR. Thavendirananthan et al. [20] compared the diagnostic accuracy of 3D-PISA method in assessing functional MR using the peak 3D-PISA and the integrated 3D-PISA derived RVol (calculated for each systolic frame) taking into account the dynamic of the MR. They showed that compared with CMR derived RVol (33 ± 22 ml), the integrated 3D-PISA derived RVol (34 ± 26 ml) was not significantly different; however, the peak 3D-PISA derived RVol was higher (48 ± 27 ml).

In the present study, 4DFindirect method performed comparably to standard 2D CMR, but with the need of additional acquisition and post-processing time. Nonetheless, 4D flow CMR may exhibit some potential translational outlooks and advantages. It permits to map out retrospectively the velocities and flow patterns throughout the whole heart, which may give a much more complete picture of the heart valve pathology, not only due to a 3D visualization of the regurgitant jet, but also because it could permit to derive advanced hemodynamic metrics (i.e. shear stress, turbulent kinetic energy, flow vorticity and helicity) which may help to better understand the pathophysiology and its relationship with clinical outcomes. Moreover, development of acceleration techniques, improved automated methods, and emerging machine learning algorithms, may improve 4D flow CMR techniques, allowing analysis of the entire cardiac hemodynamics in a retrospective manner for cross-checking quantification in case of uncertainty.

Future studies will have to validate our findings, and appraise the potential correlation of 4D flow CMR and of its derived advanced hemodynamic parameters with clinical outcomes in different scenarios, which could be of value in understanding the pathophysiology and progression to symptoms and adverse events in MVP patients.

**Study limitations**

Several limitations apply to our study. For speed-up of image data acquisition and respiratory motion compensation, 4D flow CMR utilized the combination of parallel imaging with free-breathing, navigator based scanning. While this may represent a potential source of breathing motion-related artifacts or distortion of the three-directional velocity encoding data, we found in accordance with previously published data, a high rate of artifact-free, diagnostic image quality datasets (97%) and an excellent agreement between CMR techniques [11, 15].

Moreover, 2D cine of the valves were acquired on breath hold, while 4D flow was performed with free breathing. The use of such cine-guided valve segmentation relies on a combination of two different CMR techniques and may result in spatial misalignment between cine scans and 4D flow dataset, increasing the potential for flow measurement errors. However, after excluding major misalignment, we obtained accurate and reproducible data. On the other hand, previous CMR studies with 2D flow have been carried out using the older free-breathing flow sequences, which were recommended for accurate flow measurement due to lower background offset error and better resolution [21]. Notwithstanding, with breath-hold sequences using new acceleration techniques, we obtained excellent in-plane spatial and temporal resolution with acceptable consistency with the net forward 4D flow volume measurements in a validation subgroup (n = 14).

In conventional CMR, cardiac motion causes target structures to move in and out of the image plane. This through-plane motion of the valve plane causes systematic errors in the measurement of flow, which can lead to underestimation of RVol. Exacerbated by factors like vigorous longitudinal contraction of the LV (common in severe MR). These limitations may be overcome by the use of prospective slice tracking flow CMR sequences [22], but this involves complex software programming and it is not widely available so far. These concerns have resulted in an interest in the use of 4D flow CMR sequences with retrospective valve tracking. We proposed a cine-guided valve segmentation to at least partially overcome the through-plane motion of the mitral valve and LVOT planes. These sequences are widely available and may improve the anatomical display and
delineation of the region of interest, due to the higher contrast between blood pool and surrounding structures of the balanced steady state free-precession and spoiled gradient echo sequences compared with the magnitude (anatomical) images of the 4D flow datasets. Nevertheless, they may still have introduced systematic errors in the measurement of the RVol. Despite this limitation, 4DF_{indirect} showed reasonable agreement with standard volumetric CMR quantification providing an alternative method for retrospective internal validation.

Finally, and as noted by other investigators, post-contrast 4D flow CMR data acquisition may benefit from the enhanced signal-to-noise and velocity-to-noise ratio as well as improved contrast between blood and surrounding tissue [23], which could increase the conspicuity of the MR jet on 4DF_{direct} jet analysis. Further investigation regarding the potential benefit of post-contrast 4D flow CMR is warranted.

Conclusions
Present study demonstrated that cine-guided valve segmentation 4D flow CMR for the assessment of MR in MVP is feasible and may enable comparable evaluation to standard volumetric calculation CMR, but with lower RVol when TTE is used as reference. 4DF_{indirect} method has higher intra- and inter-technique agreement than 4DF_{direct} method and might be used as an adjunctive technique for cross-checking MR quantification in MVP.

Abbreviations
4D: Four-dimensional; AoBF: Aortic diastolic backward flow volume; AoFF: Aortic systolic forward flow volume; AoSV: Aortic stroke volume; bSSFP: Balanced steady state free precession; CMR: Cardiovascular magnetic resonance; ECG: Electrocardiogram; EROA: Effective regurgitant orifice area; FCR: Flow convergence region; LV: Left ventricle/left ventricular; LVEDV: Left ventricular end-diastolic volume; LVEF: Left ventricular ejection fraction; LVESV: Left ventricular end-systolic volume; LVOT: Left ventricular outflow tract; MR: Mitral regurgitation; MV: Mitral valve; MVP: Mitral valve prolapse; PC: Phase contrast; PISA: Proximal isovelocity surface area; RF: Regurgitant fraction; RVol: Regurgitant volume; SV: Stroke volume; TTE: Transthoracic echocardiography; VC: Vena contracta.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12968-021-00783-8.

Acknowledgements
Not applicable.

Authors’ contributions
RAS, CJ, IP, GC, GH and MAB were involved in the conception and design of the study. RAS, CJ, FL, FF, MC-Z, FZ and ES were involved in data collection. RAS, CJ, IP, FL and MC-Z were involved in data analyses. RAS, CJ and IP were responsible for statistical analyses. RAS and CJ were responsible for drafting of manuscript. RAS, CJ, IP and MAB were responsible for critically revising the manuscript for important intellectual content. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed supporting the conclusions of the article are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the local research ethics committee (270-18-ek). All subjects gave written informed consent to participate.

Competing interests
One coauthor (GC) is an employee of GyroTools (GyroTools, Zurich, Switzerland) but had no control of the data. Other authors declare no competing interest or relationship with industry.

Author details
1 Department of Cardiac Surgery, Heart Center Leipzig at University of Leipzig, Struempellstrasse 39, 04289 Leipzig, Germany. 2 Department of Cardiology and Electrophysiology, Heart Center Leipzig at University of Leipzig, Struempellstrasse 39, 04289 Leipzig, Germany. 3 Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland.

Received: 26 December 2020   Accepted: 26 May 2021

Published online: 08 July 2021

References
1. Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm Pi, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.
2. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the american society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr. 2017;30(4):305–71.
3. Writing Group M, Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P, et al. ACC/AATS/AHA/ASE/ACR/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Soc Echocardiogr. 2017.
4. Uretsky S, Argulian E, Narula J, Wolf SD. Use of cardiac magnetic resonance imaging in assessing mitral regurgitation: current evidence. J Am Coll Cardiol. 2018;71(5):547–63.
5. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on
Standardized P. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.

6. Fidock B, Barker N, Balasubramanian N, Archer G, Fent G, Al-Mohammad A, et al. A systematic review of 4D-flow MRI derived mitral regurgitation quantification methods. Front Cardiovasc Med. 2019;6:103.

7. Marsan NA, Westenberg JJ, Ypenburg C, Delgado V, van Bommel RJ, Roes SD, et al. Quantification of functional mitral regurgitation by real-time 3D echocardiography: comparison with 3D velocity-encoded cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2(11):1245–52.

8. Brands A, Bertini M, van Dijk EI, Delgado V, Marsan NA, van der Geest RJ, et al. Left ventricular diastolic function assessment from three-dimensional three-directional velocity-encoded MRI with retrospective valve tracking. J Magn Reson Imaging JMRI. 2011;33(2):312–9.

9. Kamphuis VP, Roest AAW, Ajmone Marsan N, van den Boogaard PJ, Kroft LJM, Aben JP, et al. Automated cardiac valve tracking for flow quantification with four-dimensional flow MRI. Radiology. 2019;290(1):70–8.

10. Feneis JF, Kuybwa E, Atianzar K, Cheng JV, Alley MT, Vasanawala SS, et al. 4D-flow MRI quantification of mitral and tricuspid regurgitation: reproducibility and consistency relative to conventional MRI. J Magn Reson Imaging JMRI. 2018;48(4):1147–58.

11. Westenberg JJ, Roes SD, Ajmone Marsan N, Binnendijk NM, Doornbos J, Bax JJ, et al. Mitral valve and tricuspid valve blood flow: accurate quantification with 3D velocity-encoded MR imaging with retrospective valve tracking. Radiology. 2008;249(3):792–800.

12. Roes SD, Hammer S, van der Geest RJ, Marsan NA, Bax JJ, Lamb HJ, et al. Flow assessment through four heart valves simultaneously using 3-dimensional 3-directional velocity-encoded magnetic resonance imaging with retrospective valve tracking in healthy volunteers and patients with valvular regurgitation. Invest Radiol. 2009;44(10):669–75.

13. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, et al. Assessment of mitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev Cardiol. 2020;17(5):298–312.

14. Calkoen EE, Westenberg JJ, Kroft LJ, Blom NA, Hazekamp MG, Rijlaarsdam ME, et al. Characterization and quantification of dynamic eccentric regurgitation of the left atrioventricular valve after atrioventricular septal defect correction with 4D Flow cardiovascular magnetic resonance and retrospective valve tracking. J Cardiovasc Magn Reson. 2015;17:18.

15. Jacobs K, Rigdon J, Chan F, Cheng JY, Alley MT, Vasanawala S, et al. Direct measurement of atrioventricular valve regurgitant jets using 4D flow cardiovascular magnetic resonance is accurate and reliable for children with congenital heart disease: a retrospective cohort study. J Cardiovasc Magn Reson. 2020;22(1):33.

16. Fidock B, Archer G, Barker N, Elhawaz A, Al-Mohammad A, Rothman A, et al. Standard and emerging CMR methods for mitral regurgitation quantification. Int J Cardiol. 2021;331:316–21.

17. Vincenti G, Masri PG, Rutz T, De Blasi J, Prsa M, Jeanrenaud X, et al. Impact of bileaflet mitral valve prolapse on quantification of mitral regurgitation with cardiac magnetic resonance: a single-center study. J Cardiovasc Magn Reson. 2017;19(1):56.

18. Uretsky S, Gillam L, Lang R, Chaudhry FA, Argulian E, Suparwala A, et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol. 2015;65(11):1078–88.

19. Aplin M, Kyhl K, Bjerring J, Halvemann N, Greenwood JP, Plein S, et al. Cardiac remodelling and function with primary mitral valve insufficiency studied by magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2016;17(8):863–70.

20. Thavendiranathan P, Liu S, Datta S, Rajagopalan S, Ryan T, Igo SR, et al. Quantification of chronic functional mitral regurgitation by automated 3-dimensional peak and integrated proximal isovelocity surface area and stroke volume techniques using real-time 3-dimensional volume color Doppler echocardiography: in vitro and clinical validation. Circ Cardiovasc Imaging. 2013;6(1):125–33.

21. Myerson SG. Heart valve disease: investigation by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:7.

22. Kozerke S, Schwitter J, Pedersen EM, Boesiger P. Aortic and mitral regurgitation: quantification using moving slice velocity mapping. J Magn Reson Imaging JMRI. 2001;14(2):106–12.

23. Dyverfeldt P, Bissell M, Barker AJ, Bolger AF, Carlhall CJ, Ebbers T, et al. 4D flow cardiovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson. 2015;17:72.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.